Renal Phosphate Handling in Antiretroviral-naive HIV-Infected Patients. 2021

Tewogbade Adeoye Adedeji, and Simeon Adelani Adebisi, and Nife Olamide Adedeji, and Olusola Akanni Jeje, and Rotimi Samuel Owolabi
Department of Chemical Pathology, Obafemi Awolowo University, Ile-Ife, Nigeria.

BACKGROUND Human immunodeficiency virus (HIV) infection impairs renal function, thereby affecting renal phosphate metabolism. OBJECTIVE We prospectively estimated the prevalence of phosphate abnormalities (mild, moderate to life-threatening hypophosphataemia, and hyperphosphataemia) before initiating antiretroviral therapy (ART). METHODS A cross-sectional analysis was performed on 170 consecutive newly diagnosed ARTnaive, HIV-infected patients attending our HIV/AIDS clinics over a period of one year. Fifty (50) screened HIV-negative blood donors were used for comparison (controls). Blood and urine were collected simultaneously for phosphate and creatinine assay to estimate fractional phosphate excretion (FEPi %) and glomerular filtration rate (eGFR). RESULTS eGFR showed significant difference between patients' and controls' medians (47.89ml/ min/1.73m2 versus 60ml/min/1.73m2, p <0.001); which denotes a moderate chronic kidney disease in the patients. Of the 170 patients, 78 (45.9%) had normal plasma phosphate (0.6-1.4 mmol/L); 85 (50%) had hyperphosphataemia. Grades 1, 2 and 3 hypophosphataemia was observed in 3 (1.8%), 3 (1.8%), and 1(0.5%) patient(s) respectively. None had grade 4 hypophosphataemia. Overall, the patients had significantly higher median of plasma phosphate than the controls, 1.4 mmol/L (IQR: 1.0 - 2.2) versus 1.1 mmol/L (IQR: 0.3 - 1.6), p <0.001, implying hyperphosphataemia in the patients; significantly lower median urine phosphate than the controls, 1.5 mmol/L (IQR: 0.7 -2.1) versus 8.4 mmol/L (IQR: 3.4 - 16), p <0.001), justifying the hyperphosphataemia is from phosphate retention; but a non-significantly lower median FEPi% than the controls, 0.96% (IQR: 0.3 -2.2) versus 1.4% (IQR: 1.2 -1.6), p > 0.05. Predictors of FEPi% were age (Odds ratio, OR 0.9, p = 0.009); weight (OR 2.0, p < 0.001); CD4+ cells count predicted urine phosphate among males (p = 0.029). CONCLUSIONS HIV infection likely induces renal insufficiency with reduced renal phosphate clearance. Thus, hyperphosphataemia is highly prevalent, and there is mild to moderate hypophosphataemia but its life-threatening form (grade 4) is rare among ART-naive HIV patients.

UI MeSH Term Description Entries
D007668 Kidney Body organ that filters blood for the secretion of URINE and that regulates ion concentrations. Kidneys
D008297 Male Males
D010710 Phosphates Inorganic salts of phosphoric acid. Inorganic Phosphate,Phosphates, Inorganic,Inorganic Phosphates,Orthophosphate,Phosphate,Phosphate, Inorganic
D003430 Cross-Sectional Studies Studies in which the presence or absence of disease or other health-related variables are determined in each member of the study population or in a representative sample at one particular time. This contrasts with LONGITUDINAL STUDIES which are followed over a period of time. Disease Frequency Surveys,Prevalence Studies,Analysis, Cross-Sectional,Cross Sectional Analysis,Cross-Sectional Survey,Surveys, Disease Frequency,Analyses, Cross Sectional,Analyses, Cross-Sectional,Analysis, Cross Sectional,Cross Sectional Analyses,Cross Sectional Studies,Cross Sectional Survey,Cross-Sectional Analyses,Cross-Sectional Analysis,Cross-Sectional Study,Cross-Sectional Surveys,Disease Frequency Survey,Prevalence Study,Studies, Cross-Sectional,Studies, Prevalence,Study, Cross-Sectional,Study, Prevalence,Survey, Cross-Sectional,Survey, Disease Frequency,Surveys, Cross-Sectional
D005919 Glomerular Filtration Rate The volume of water filtered out of plasma through glomerular capillary walls into Bowman's capsules per unit of time. It is considered to be equivalent to INULIN clearance. Filtration Rate, Glomerular,Filtration Rates, Glomerular,Glomerular Filtration Rates,Rate, Glomerular Filtration,Rates, Glomerular Filtration
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D015658 HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS). HTLV-III Infections,HTLV-III-LAV Infections,T-Lymphotropic Virus Type III Infections, Human,HIV Coinfection,Coinfection, HIV,Coinfections, HIV,HIV Coinfections,HIV Infection,HTLV III Infections,HTLV III LAV Infections,HTLV-III Infection,HTLV-III-LAV Infection,Infection, HIV,Infection, HTLV-III,Infection, HTLV-III-LAV,Infections, HIV,Infections, HTLV-III,Infections, HTLV-III-LAV,T Lymphotropic Virus Type III Infections, Human
D019380 Anti-HIV Agents Agents used to treat AIDS and/or stop the spread of the HIV infection. These do not include drugs used to treat symptoms or opportunistic infections associated with AIDS. AIDS Drug,AIDS Drugs,Anti-AIDS Agents,Anti-AIDS Drug,Anti-HIV Agent,Anti-HIV Drug,Anti-AIDS Drugs,Anti-HIV Drugs,Agent, Anti-HIV,Agents, Anti-AIDS,Agents, Anti-HIV,Anti AIDS Agents,Anti AIDS Drug,Anti AIDS Drugs,Anti HIV Agent,Anti HIV Agents,Anti HIV Drug,Anti HIV Drugs,Drug, AIDS,Drug, Anti-AIDS,Drug, Anti-HIV,Drugs, AIDS,Drugs, Anti-AIDS,Drugs, Anti-HIV

Related Publications

Tewogbade Adeoye Adedeji, and Simeon Adelani Adebisi, and Nife Olamide Adedeji, and Olusola Akanni Jeje, and Rotimi Samuel Owolabi
January 2010, Journal of acquired immune deficiency syndromes (1999),
Tewogbade Adeoye Adedeji, and Simeon Adelani Adebisi, and Nife Olamide Adedeji, and Olusola Akanni Jeje, and Rotimi Samuel Owolabi
June 2013, Journal of the International Association of Providers of AIDS Care,
Tewogbade Adeoye Adedeji, and Simeon Adelani Adebisi, and Nife Olamide Adedeji, and Olusola Akanni Jeje, and Rotimi Samuel Owolabi
October 2009, The Journal of antimicrobial chemotherapy,
Tewogbade Adeoye Adedeji, and Simeon Adelani Adebisi, and Nife Olamide Adedeji, and Olusola Akanni Jeje, and Rotimi Samuel Owolabi
January 2020, AIDS (London, England),
Tewogbade Adeoye Adedeji, and Simeon Adelani Adebisi, and Nife Olamide Adedeji, and Olusola Akanni Jeje, and Rotimi Samuel Owolabi
October 2015, AIDS (London, England),
Tewogbade Adeoye Adedeji, and Simeon Adelani Adebisi, and Nife Olamide Adedeji, and Olusola Akanni Jeje, and Rotimi Samuel Owolabi
March 2006, Lancet (London, England),
Tewogbade Adeoye Adedeji, and Simeon Adelani Adebisi, and Nife Olamide Adedeji, and Olusola Akanni Jeje, and Rotimi Samuel Owolabi
June 2009, The Journal of antimicrobial chemotherapy,
Tewogbade Adeoye Adedeji, and Simeon Adelani Adebisi, and Nife Olamide Adedeji, and Olusola Akanni Jeje, and Rotimi Samuel Owolabi
January 1999, Antiviral therapy,
Tewogbade Adeoye Adedeji, and Simeon Adelani Adebisi, and Nife Olamide Adedeji, and Olusola Akanni Jeje, and Rotimi Samuel Owolabi
August 2012, World journal of pediatrics : WJP,
Tewogbade Adeoye Adedeji, and Simeon Adelani Adebisi, and Nife Olamide Adedeji, and Olusola Akanni Jeje, and Rotimi Samuel Owolabi
June 2009, AIDS (London, England),
Copied contents to your clipboard!